期刊
ONCOTARGET
卷 7, 期 45, 页码 73697-73710出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.12048
关键词
PI; proteasome inhibitor; CFZ; carfilzomib; DOX; doxorubicin; DMSO; dimethyl sulfoxide; FDA; Food and Drug Administration
资金
- University Cancer Foundation via Institutional Research Grant Program at the University of Texas MD Anderson Cancer Center
- China Scholarship Council [201408655107]
Proteasome inhibition is an attractive approach for anticancer therapy. Doxorubicin (DOX) is widely used for treatment in a number of cancers including breast cancer; however, the development of DOX resistance largely limits its clinical application. One of the possible mechanisms of DOX-resistance is that DOX might induce the activation of NF-kappa B. In this case, proteasome inhibitors could inhibit the activation of NF-kappa B by blocking inhibitory factor kappa B (I kappa B) degradation. Carfilzomib, a second-generation proteasome inhibitor, overcomes bortezomib resistance and lessens its side-effects. Currently, the effect of carfilzomib on breast cancer cell proliferation remains unclear. In this study, we exploited the role of carfilzomib in seven breast cancer cell lines, MCF7, T-47D, MDA-MB-361, HCC1954, MDA-MB-468, MDA-MB-231, and BT-549, representing all major molecular subtypes of breast cancer. We found that carfilzomib alone had cytotoxic effects on the breast cancer cells and it increased DOX-induced cytotoxic effects and apoptosis in combination by enhancing DOX-induced JNK phosphorylation and inhibiting DOX-induced I kappa B alpha degradation. The results suggest that carfilzomib has potent antitumor effects on breast cancer in vitro and can sensitize breast cancer cells to DOX treatment. DOX in combination with carfilzomib may be an effective and feasible therapeutic option in the clinical trials for treating breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据